Project Grant R01DK144860
- This Project Grant award of $200,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research to investigate the role of oxidative stress and the transcription factor Nrf2 in modulating the phenotype of vascular smooth muscle cells (VSMCs) and improving arteriovenous fistula (AVF) maturation. The research, to be conducted at the University of North...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing novel bioengineered regenerative medicine solutions based on vasculogenic regenerative medicine technology. The $543,826 award, granted on December 10, 2024, aims to investigate the mechanisms underlying in vivo vasculogenic reprogramming, specifically examining...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $437,010 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of North Carolina at Chapel Hill. The grant, titled "Leveraging 'Smart Stent' Platform Technologies for AVF Maturation and More", aims to develop and test a biodegradable magnesium "smart stent" technology to improve early blood flow and minimize stenosis...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health, awarded a $350,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Microvascular Tissues, Inc. The grant supports the evaluation of a microvascular tissue graft treatment in rat models of diabetic peripheral neuropathy. The project aims to assess the ability of this novel microvascular tissue graft to improve...
- This $532,177 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847), supports research to investigate a novel inflammatory pathway in diabetic kidney disease (DKD). The research aims to elucidate the role of the transcription modulator I-MFA in regulating inflammatory cytokine production by glomerular mesangial cells, a key contributor to DKD pathogenesis. The 4-year project at the University of North Texas Health Science Center will...
- This federal Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing a new class of biodegradable and elastic vascular grafts for hemodialysis. The $298,371 award to Anova Biomedical, Inc. aims to address the limitations of current expanded polytetrafluoroethylene (ePTFE) arteriovenous grafts, which have high failure rates...
- This $128,286 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research into the mechanisms of renal lipotoxicity and its contribution to the development of chronic kidney disease (CKD). The principal investigator will investigate the protective role of the FAF2 gene knockout in mitigating palmitate-induced lipotoxicity in...
- This federal Project Grant award of $690,451 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the role of bladder fibroblasts in regulating bladder function. The University of Pittsburgh will conduct studies to investigate the contractile properties of suburothelial fibroblasts and their contribution to the formation of bladder rugae, as well as the involvement of...
- This federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $306,867 award to Dupage Medical Technology Inc. supports the development of a new drug to treat ischemia-reperfusion injury associated with kidney transplantation. The project aims to develop a therapy that can reduce inflammation and thrombosis without causing excessive...
- This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the molecular mechanisms driving the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). The $1,491,303 award to The Washington University aims to characterize how the repression of the FOXM1-CCNF axis during tubular epithelial...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on investigating the role of vascular fibroblasts in postoperative venous stenosis. The $2,777,206 award to the University of Miami aims to demonstrate the central role of venous fibroblasts in the stenotic remodeling of arteriovenous fistulas (AVFs) created for dialysis in end-stage kidney disease patients. The project will utilize molecular and cellular approaches, including in vivo and in vitro models, to explore the mechanisms by which fibroblasts and myofibroblasts control postoperative inflammation, medial fibrosis, and intimal expansion leading to AVF stenosis. The ultimate goal is to determine if genetic and pharmacological inhibition of collagen VIII biosynthesis in venous fibroblasts can improve AVF maturation by decreasing inflammation, myofibroblast accumulation, and vascular wall stiffness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.8m | 9/21/25 |